--- title: "ALX Oncology Holdings (ALXO) news: offering" url: "https://aibio.space/companies/alx-oncology/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ALXO offering news: ALX Oncology raises $150 million at $1.57 a share, led by RA Capital and TCGX. ALX Oncology Holdings Inc. (NASDAQ: ALXO), United States." --- ALXO ALX Oncology Holdings Inc. NASDAQ · United States # ALX Oncology Holdings (ALXO) news ALXO offering news Financings · 2026-10-15 ## [ALX Oncology swaps 13,353,384 shares for pre-funded warrants with investors](https://aibio.space/news/alx-oncology-swaps-13-353-384-shares-pre-funded-warrants-investors/) ALX Oncology's exchange trades 13,353,384 common shares for pre-funded warrants with a $0.001 exercise price, and the 8-K describes no cash payment to the company. ## Latest ALX Oncology Holdings news 1. 2026-06-25 Debt Financing [ALX Oncology closes up to $50,000,000 HSBC term loan facility](https://aibio.space/news/alx-oncology-closes-up-50-000-000-hsbc-term-loan-facility/) ALX Oncology borrowed $10,000,000 at closing from HSBC Ventures USA and used it to refinance its Oxford Finance and Silicon Valley Bank loan. The facility can reach $50,000,000, but $10,000,000 of that is uncommitted and the rest depends on draw dates and milestones. 2. 2026-01-30 Financings [ALX Oncology raises $150 million at $1.57 a share, led by RA Capital and TCGX](https://aibio.space/news/alx-oncology-raises-150-million-1-57-share-led-ra-capital-tcgx/) ALX Oncology priced 76,979,112 shares and pre-funded warrants for 18,574,120 more, at $1.57 a share, after a year of failed or dropped combination trials and a narrower focus on its CD47 drug evorpacept. 3. 2025-03-05 Distress [ALX Oncology approves 30% workforce reduction, will eliminate president and CSO role](https://aibio.space/news/alx-oncology-approves-30-percent-workforce-reduction-will-eliminate/) ALX Oncology's board approved a cut of about 30% of staff on Feb 28, 2025, and eliminates its president and chief scientific officer role. The company estimates about $2.2 million in severance and benefits for a lead drug that has not completed a pivotal trial. ## ALX Oncology Holdings at a glance - **Ticker**: ALXO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $138.2 million ### Related companies - [Korsana Biosciences](https://aibio.space/companies/korsana-biosciences/) NASDAQ: KRSA - [SpyGlass Pharma](https://aibio.space/companies/spyglass-pharma/) NASDAQ: SGP - [Manhattan Scientifics](https://aibio.space/companies/manhattan-scientifics/) OTC: MHTX - [Heron Therapeutics](https://aibio.space/companies/heron-therapeutics/) NASDAQ: HRTX - [CG Oncology](https://aibio.space/companies/cg-oncology/) NASDAQ: CGON - [Lineage Cell Therapeutics](https://aibio.space/companies/lineage-cell-therapeutics/) AMEX: LCTX - [GRI Bio](https://aibio.space/companies/gri-bio/) NASDAQ: GRI - [Zentalis Pharmaceuticals](https://aibio.space/companies/zentalis-pharmaceuticals/) NASDAQ: ZNTL ### Also on NASDAQ - [Neurogene](https://aibio.space/companies/neurogene/) NGNE - [biote](https://aibio.space/companies/biote/) BTMD - [NOMAD POWER SOLUTIONS, INC.](https://aibio.space/companies/nomad-power-solutions/) NMAD - [Research Alliance Corp III](https://aibio.space/companies/research-alliance-iii/) RACC - [Greenland Mines](https://aibio.space/companies/greenland-mines/) GRML - [Kazia Therapeutics](https://aibio.space/companies/kazia-therapeutics/) KZIA ## What ALX Oncology Holdings does ALX Oncology Holdings Inc. is a clinical-stage biotechnology company developing novel therapies to treat cancer. Its lead product candidate, evorpacept, is a CD47 blocker that combines a high-affinity CD47 binding domain with a proprietary inactivated Fc domain. The company designs evorpacept for combination with other anti-cancer agents that provide a positive immune-stimulating signal, and says that clinical data to date have not shown the dose-dependent hematologic toxicities seen with other CD47 blockers that have an active Fc domain. Evorpacept is being evaluated with trastuzumab and chemotherapy in patients with metastatic HER2-positive breast cancer in the Phase 2 ASPEN-09-Breast trial. The company describes the randomized ASPEN-06 Phase 2 trial in gastric cancer as supporting the clinical validation of this mechanism. The company says approximately 800 subjects have been treated with evorpacept in combination with targeted anti-cancer agents, small molecules and checkpoint inhibitors. Its second pipeline candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate that entered a Phase 1 clinical trial in August 2025. | Product or program | What it is | Stage | |---|---|---| | Evorpacept | CD47 blocker fusion protein for cancers that over-express CD47, used in combination therapy | Phase 2 (ASPEN-09-Breast) | | ALX2004 | EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action | Phase 1 trial entered in August 2025 | Summarised from the company's [10-K filed Mar 9, 2026](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/alxo-20251231.htm). ## ALX Oncology Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$77.0 million](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/) | [$116.4 million](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/) | | Net income (loss) | [-$101.7 million](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/) | [-$134.8 million](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/) | | Cash from operations | [-$84.1 million](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/) | [-$121.9 million](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/) | | Cash and equivalents | [$16.4 million](https://www.sec.gov/Archives/edgar/data/1810182/000119312526337920/) | [$17.6 million](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/) | | Short-term investments | [$28.4 million](https://www.sec.gov/Archives/edgar/data/1810182/000119312526337920/) | [$110.2 million](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $22.7 million, plus short-term investments of $115.5 million, $138.2 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Analysis - Opinion Mixed view 2026-10-28 [ALX Oncology has about 23 months of cash on our math, and the date is tight](https://aibio.space/analysis/alx-oncology-has-about-23-months-cash-our-math-date-tight/) Our arithmetic gives about 23 months, close to the company's first half of 2028 date. The best response rate comes from a 43-patient subgroup, and the FDA has said the gastric data cannot support accelerated approval. Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/). ## Questions about ALX Oncology Holdings Has ALX Oncology Holdings raised money recently? Our latest story on this, dated Jan 30, 2026: "ALX Oncology raises $150 million at $1.57 a share, led by RA Capital and TCGX". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alx-oncology-raises-150-million-1-57-share-led-ra-capital-tcgx/). What is the ticker symbol of ALX Oncology Holdings? ALX Oncology Holdings Inc. trades under the ticker ALXO on NASDAQ. Where is ALX Oncology Holdings listed? ALX Oncology Holdings Inc. is listed on NASDAQ. What is the SEC CIK of ALX Oncology Holdings? The SEC Central Index Key (CIK) for ALX Oncology Holdings Inc. is 1810182. Its filings are on SEC EDGAR. How many shares does ALX Oncology Holdings have outstanding? 138,276,997 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is ALX Oncology Holdings listed under? Our directory records ALX Oncology Holdings Inc. under United States. What does ALX Oncology Holdings do? Our directory classifies ALX Oncology Holdings Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of ALX Oncology Holdings? The ISIN recorded for ALX Oncology Holdings Inc. is US00166B1052. Does aibio.space cover ALX Oncology Holdings? aibio.space lists ALX Oncology Holdings Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is ALX Oncology Holdings incorporated? SEC records list its state or country of incorporation as DE. What does ALX Oncology Holdings develop? ALX Oncology Holdings Inc. is a clinical-stage biotechnology company developing novel therapies to treat cancer. Its lead product candidate, evorpacept, is a CD47 blocker that combines a high-affinity CD47 binding domain with a proprietary inactivated Fc domain. What is Evorpacept from ALX Oncology Holdings? Evorpacept: CD47 blocker fusion protein for cancers that over-express CD47, used in combination therapy Stage: Phase 2 (ASPEN-09-Breast). What is ALX2004 from ALX Oncology Holdings? ALX2004: EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action Stage: Phase 1 trial entered in August 2025. Is ALX Oncology Holdings profitable? ALX Oncology Holdings Inc. reported a net loss of $101.7 million for the fiscal year ended Dec 31, 2025, and used $84.1 million of cash in operations, per its annual report to the SEC. How much does ALX Oncology Holdings spend on research and development? $77.0 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: ALX Oncology Holdings Members talk about ALX Oncology Holdings (ALXO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ALX Oncology Holdings, newest first. Each line links the filing it comes from. 1. 2026-10-15 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810182/000119312526422992/alxo-20261014.htm) 2. 2026-06-26 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810182/000119312526285425/alxo-20260625.htm) 3. 2026-01-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810182/000119312526030579/d12882dex991.htm) 4. 2025-09-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810182/000181018225000006/alxo-ex99_1.htm) 5. 2025-04-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1810182/000095017025058687/alxo-20250423.htm) 6. 2025-03-06 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1810182/000119312525048564/d938483ds3.htm) 7. 2025-03-05 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02). [Source](https://www.sec.gov/Archives/edgar/data/1810182/000095017025033504/alxo-20250228.htm) 8. 2024-12-02 Financings Offered to buy back its own securities. SEC Form SC TO-I. [Source](https://www.sec.gov/Archives/edgar/data/1810182/000119312524268885/d898496dsctoi.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ALXO on TradingView](https://www.tradingview.com/symbols/NASDAQ-ALXO/). ## SEC filings and registration - **SEC name**: Alx Oncology Holdings Inc - **CIK**: 1810182 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ALXO (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: 650-466-7125 - **Shares outstanding**: 138,276,997 as of 2026-07-30 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1810182/000119312526422992/alxo-20261014.htm) filed 2026-10-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1810182/000119312526337920/alxo-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1810182/000119312526336843/alxo-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1810182/000119312526290447/alxo-20260629.htm) filed 2026-06-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1810182/000119312526285425/alxo-20260625.htm) filed 2026-06-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1810182/000119312526267472/alxo-20260610.htm) filed 2026-06-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1810182/000119312526213399/alxo-20260331.htm) filed 2026-05-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1810182/000119312526213380/alxo-20260508.htm) filed 2026-05-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001810182), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ALX Oncology Holdings Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ALXO, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ALX Oncology Holdings Inc. - **Ticker**: ALXO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US00166B1052 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ALXO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/alx-oncology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ALX Oncology Holdings (ALXO) news: offering", 2026-10-31, https://aibio.space/companies/alx-oncology/